Literature DB >> 2543629

Purification and antimicrobial properties of three defensins from rat neutrophils.

P B Eisenhauer1, S S Harwig, D Szklarek, T Ganz, M E Selsted, R I Lehrer.   

Abstract

Three cysteine-rich cationic peptides, designated RatNP-1, RatNP-3, and RatNP-4, were purified from an acid extract of rat polymorphonuclear neutrophils, sequenced, and tested for antimicrobial activity. The peptides ranged from 29 to 32 amino acids in length (Mr, 3,252 to 3,825), and each contained all eight invariantly conserved "framework" residues that are characteristic of defensins. Each of the peptides killed Escherichia coli ML-35, Acinetobacter calcoaceticus HON-1, Staphylococcus aureus 502A, and Candida albicans 820 in vitro. RatNP-1, the most cationic rat defensin, was also the most potent. With this report, a total of 13 distinct defensins have been characterized in the polymorphonuclear leukocytes of four mammalian species. The existence of the defensin system in rats should facilitate investigations of the in vivo role of defensins in experimental infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543629      PMCID: PMC313836          DOI: 10.1128/iai.57.7.2021-2027.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Antibacterial activity of cationic proteins from human granulocytes.

Authors:  H Odeberg; I Olsson
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

2.  Small, antibacterial and large, inactive peptides of neutrophil granules share immunoreactivity to a monoclonal antibody.

Authors:  R Marzari; B Scaggiante; B Skerlavaj; M Bittolo; R Gennaro; D Romeo
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

3.  Association of lactoferrin with lysozyme in granules of human polymorphonuclear leukocytes.

Authors:  M S Leffell; J K Spitznagel
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

4.  Spiral plate count method for the examination of raw and pasteurized milk.

Authors:  C B Donnelly; J E Gilchrist; J T Peeler; J E Campbell
Journal:  Appl Environ Microbiol       Date:  1976-07       Impact factor: 4.792

5.  Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells.

Authors:  I Olsson; P Venge
Journal:  Blood       Date:  1974-08       Impact factor: 22.113

6.  Natural host resistance to infection with Cryptococcus neoformans. IV. The effect of some cationic proteins on the experimental disease.

Authors:  H H Gadebusch; A G Johnson
Journal:  J Infect Dis       Date:  1966-12       Impact factor: 5.226

7.  Solution structures of the rabbit neutrophil defensin NP-5.

Authors:  A Pardi; D R Hare; M E Selsted; R D Morrison; D A Bassolino; A C Bach
Journal:  J Mol Biol       Date:  1988-06-05       Impact factor: 5.469

8.  Mechanisms for the microbicidal activity of cationic proteins of human granulocytes.

Authors:  H Odeberg; I Olsson
Journal:  Infect Immun       Date:  1976-12       Impact factor: 3.441

9.  Inhibition by lysozyme of growth of the spherule phase of Coccidioides immitis in vitro.

Authors:  M S Collins; D Pappagianis
Journal:  Infect Immun       Date:  1974-09       Impact factor: 3.441

10.  Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes.

Authors:  A Janoff; J Scherer
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  29 in total

Review 1.  Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells.

Authors:  T Ganz; A Oren; R I Lehrer
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes.

Authors:  B L Kagan; M E Selsted; T Ganz; R I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Strain-specific polymorphisms in Paneth cell α-defensins of C57BL/6 mice and evidence of vestigial myeloid α-defensin pseudogenes.

Authors:  Michael T Shanahan; Hiroki Tanabe; André J Ouellette
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

Review 4.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 5.  Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development.

Authors:  Colleen R Eade; Matthew P Wood; Alexander M Cole
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

6.  Alpha-4/beta-1 and alpha-L/beta-2 integrins mediate cytokine induced lung leukocyte-epithelial adhesion and injury.

Authors:  L A Parmley; N D Elkins; M A Fini; Y-E Liu; J E Repine; R M Wright
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

7.  Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.

Authors:  M S Alcouloumre; M A Ghannoum; A S Ibrahim; M E Selsted; J E Edwards
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells.

Authors:  Aisling S Dugan; Melissa S Maginnis; Joslynn A Jordan; Megan L Gasparovic; Kate Manley; Rebecca Page; Geoffrey Williams; Edith Porter; Bethany A O'Hara; Walter J Atwood
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

9.  Localization of human neutrophil peptide (HNP) and its messenger RNA in neutrophil series.

Authors:  Y Date; M Nakazato; K Shiomi; H Toshimori; K Kangawa; H Matsuo; S Matsukura
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

10.  Purification of equine neutrophil lysozyme and its antibacterial activity against gram-positive and gram-negative bacteria.

Authors:  A Pellegrini; S Waiblinger; R Von Fellenberg
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.